Technology | Lung Cancer | August 28, 2017

20/20 GeneSystems Launches AI-Based Lung Cancer Detection Technology in China

Platform represents first machine learning approach available to hospitals to aid in evaluating ambiguous pulmonary nodules

20/20 GeneSystems Launches AI-Based Lung Cancer Detection Technology in China

August 28, 2017 — 20/20 GeneSystems Inc. recently released in China what is believed to be the world’s first machine learning algorithm commercialized for use in conjunction with blood tests to aid in the early detection of lung cancer. The cloud-accessible software, marketed in China by MyBioMed Ltd., is expected to be utilized over the next six months by at least 20 hospitals in five or more cities to help in distinguishing between benign versus malignant pulmonary nodules following computed tomography (CT) imaging.

The algorithm, built and validated with data from over 1,000 patients tested at the Tianjin Cancer Institute combines the values of biomarker — tumor-associated proteins in the blood — and individual patient characteristics such as their age, smoking status and nodule size. It could potentially increase the number of cancers detected by more than 50 percent over current methods. Artificial neural networks are incorporated to permit continuous improvements as more data is acquired over time.

Lung cancer is a significant burden in China as more than half of adult men in that country are current or former smokers and heavy air pollution further contributes to the disease. "Lung cancer in China has a very high disease incidence and the current solution is to do early screening which often leads to good outcomes at a low cost,” said Yilong Wu, M.D. chair of the Chinese Society of Clinical Oncology and himself a chest surgeon and lung cancer expert. “Low-dose CT (LDCT) screening has been recognized worldwide as an approach to reduce lung cancer mortality but these scans uncover many nodules that turn out to be benign, and unneeded biopsies and surgery can be dangerous to many patients,” he added. “I am very optimistic about the approach introduced by 20/20 and MBM of adding bioinformatics and artificial intelligence methods to improve the sensitivity and specificity of detection and look forward to seeing continued expansion of their data sets and confirmatory studies."

20/20’s cloud-based lung nodule assessment software is the company’s first product marketed using a software-as-a-service (SaaS) revenue model, according to 20/20 CEO Jonathan Cohen.

For more information:

Related Content

Graphic courtesy of Pixabay

Graphic courtesy of Pixabay

Feature | Artificial Intelligence | April 22, 2019 | By Greg Freiherr
Video Plus Brochure Helps Patients Make Lung Cancer Scan Decision

Image courtesy of the American Thoracic Society

News | Lung Cancer | April 19, 2019
A short video describing the potential benefits and risks of low-dose computed tomography (CT) screening for lung...
FDA Clears GE's Deep Learning Image Reconstruction Engine
Technology | Computed Tomography (CT) | April 19, 2019
GE Healthcare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) of its Deep Learning Image...
Artificial Intelligence Performs As Well As Experienced Radiologists in Detecting Prostate Cancer
News | Artificial Intelligence | April 18, 2019
University of California Los Angeles (UCLA) researchers have developed a new artificial intelligence (AI) system to...
Atrium Health Debuts Amazon Alexa Skill to Help Patients Access Medical Care
News | Artificial Intelligence | April 18, 2019
Atrium Health patients will now be able to use Amazon’s electronic voice system Alexa to not only locate the nearest...
Oxipit Introduces Multilingual Support for ChestEye AI Imaging Suite
News | Artificial Intelligence | April 16, 2019
The CE-certified ChestEye artificial intelligence (AI) imaging suite by Oxipit is now available in seven European...
iCAD Appoints Stacey Stevens as President
News | Radiology Business | April 16, 2019
iCAD Inc. recently announced that Stacey Stevens has been named president. As president, Stevens will have expanded...
Ebit and DiA Imaging Analysis Partner on AI-based Cardiac Ultrasound Analysis
News | Cardiovascular Ultrasound | April 16, 2019
DiA Imaging Analysis has partnered with the Italian healthcare IT company Ebit (Esaote Group), to offer DiA’s LVivo...
Radiology Publishes Roadmap for AI in Medical Imaging
News | Artificial Intelligence | April 16, 2019
In August 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Md., to explore the future...